GABA_A receptor antisense epilepsy: Histological changes following infusion of antisense oligodeoxynucleotide to GABA_A receptor γ2 subunit into rat hippocampus

REFERENCES

• Sieghart W. Structure and pharmacology of y-aminobutyric acidA receptor subtypes. Pharmacol Rev 1995; 47: 181–234
   PubMed Web of Science ®Google Scholar
• Mehta AK, Ticku MK. An update on GABAA receptors. Brain Res Rev 1999; 29: 196–217
   PubMed Web of Science ®Google Scholar
• Olsen RW, Avoli M. GABA and epileptogenesis. Epilepsia 1997; 38: 399–407
   PubMed Web of Science ®Google Scholar
• Davidkova G, Weiss B. Pharmacological inhibition of dopaminer-gic and other neurotransmittr receptors using antisense oligo-deoxynucleotides. In: Crooke ST, ed. Antisense Research and Application, Berlin: Springer, 1998: pp. 263–308
   Google Scholar
• Nicot A, Pfaff DW. Antisense oligodeoxynucleotides as specific tools for studying neuroendocrine and behavioral functions: Some prospects and problems. ] Neurosci Methods 1997; 71: 45–53
   PubMed Web of Science ®Google Scholar
• Karle J, Woldbye DPD, Elster L, Diemer NH, Bolwig TG, Olsen RW, Nielsen M. Antisense oligonucleotide to GABAA receptor y2 subunit induces limbic status epilepticus.J Neurosci Res 1998; 54: 863–869
   PubMed Web of Science ®Google Scholar
• Karle J, Witt M-R, Nielsen M. Antisense oligonucleotideto GABAA receptor y2 subunit induces loss of neurones in rat hippocampus. Neurosci Lett 1995; 202: 97–100
   PubMed Web of Science ®Google Scholar
• Karle J, Witt M-R, Nielsen M. Diazepam protects against rat hippocampal neuronal cell death induced by antisense oligode-oxynucleotideto GABAA receptory2 subunit. Brain Res 1997; 765: 21–29
   PubMedGoogle Scholar
• Sloviter RS. Decreased hippocampal inhibition and a selective loss of interneurons in experimental epilepsy. Science 1987; 235: 73–76
   PubMed Web of Science ®Google Scholar
• Treiman DM. Status epilepticus. Baillieres Clin Neurol 1996; 5: 821–839
   PubMedGoogle Scholar
• Young GB, Jordan KG. Do nonconvulsive seizures damage the brain? — Yes. Arch Neuron 998; 55: 117-119
   Google Scholar
• Belluardo N, Mudo G, Jiang XH, Condorelli DF. Induction of astroglial gene expression by experimental seizures in the rat: Spatio—temporal patterns of the early stages. Glia 1996; 16: 174–186
   PubMed Web of Science ®Google Scholar
• Shivers BD, Killisch I, Sprengel R, Sontheimer H, Köhler M, Schofield PR, Seeburg PH. Two novel GABAA receptor subunits exist in distinct neuronal subpopulations. Neuron 1989; 3: 327–337
   PubMed Web of Science ®Google Scholar
• Karle J, Laudrup P, Sams-Dodd F, Mikkelsen JD, Nielsen M. Differential changes in induced seizures after hippocampal treatment of rats with an antisense oligodeoxynucleotide to the GABAA receptor y2 subunit. Eur J Pharmaco 11997; 340: 153-160
   Google Scholar
• Auer RN, Kalimo H, Olsson Y, Siesjo BK. The temporalevolution of hypoglycemic brain damage. I. Light and electron microscopic findings in the rat cerebral cortex. Acta Neuropathol (Berl) 1985; 67: 13–24
   PubMed Web of Science ®Google Scholar
• Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates, New York: Academic Press, 1982
   Google Scholar
• Szklarczyk A, Kaczmarek L. Antisense oligodeoxyribonucleotides: Stability and distribution after intracerebral injection into rat brain. J Neurosci Methods 1995; 60: 181–187
   PubMed Web of Science ®Google Scholar
• Yaida Y, Nowak TS Jr. Distribution of phosphodiester and phosphorothioateoligon ucleotides in rat brain after intraventricular and intrahippocampal administration determined by in situ hybridization. Regul Peptides 1995; 59: 193–199
   PubMedGoogle Scholar
• Landgraf R. Antisense targeting in behavioural neuroendo-crinology. J Endocrino 11996; 151: 333-340
   Google Scholar
• Chiasson BJ, Armstrong JN, Hooper ML, Murphy PR, Robertson HA. The application of antisense oligonucleotidetechnologyto the brain: Some pitfalls. Cell Mol Neurobio 11994; 14: 507-521
   Google Scholar
• Neumann I. Antisense oligonucleotides in neuroendocrinology: Enthusiasm and frustration. Neurochem Int 1997; 31: 363–378
   PubMed Web of Science ®Google Scholar
• Whitesell L, Geselowitz D, Chavany C, Fahmy B, Walbridge S, Alger JR, Neckers LM. Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: Implica-tions for therapeutic application within the central nervous system. Proc Natl Acad Sci USA 1993; 90: 4665–4669
   PubMed Web of Science ®Google Scholar
• Le Corre SM, Burnet PW, Meller R, Sharp T, Harrison PJ. Critical issues in the antisense inhibition of brain gene expression in vivo: Experiences targetting the 5-HT1 A receptor. Neurochem Int 1997; 31: 349–362
   PubMed Web of Science ®Google Scholar
• Pezeshki G, Schöbitz B, Pohl T, Reul JMHM. Intracerebroventri-cular administration of missense oligodeoxynucleotide induces interleukin-6 m RNA expression in brain and spleen of rats. Neurosci Lett 1996; 217: 97–100
   PubMed Web of Science ®Google Scholar
• Schöbitz B, Pezeshki G, Probst JC, Reu I JMHM, Skutella T, Stöhr T, Holsboer F, Spanagel R. Centrally administered oligodeoxynucleo-tides in rats: Occurrence of non-specific effects. Eur J Pharmacol 1997; 331: 97–107
   PubMed Web of Science ®Google Scholar
• Meldrum BS, Corsellis JAN. Epilepsy. In: Adams JH, Corsellis JAN, Duchen LW, eds. Green field's Neuropathology, 4th edn, London: Edward Arnold, 1984: pp. 921-950
   Google Scholar
• Sloviter RS. On the relationship between neuropathology and pathophysiology in the epileptic hippocampus of humans and experimental animals. Hippocampus 1994; 4: 250–253
   PubMed Web of Science ®Google Scholar
• Ben-An i Y. Limbic seizure and brain damage produced by kainic acid: Mechanisms and relevanceto human temporal lobe epilepsy. Neuroscience 1985; 14: 375–403
   PubMed Web of Science ®Google Scholar
• Sperk G. Ka inic acid seizures in the rat. Prog Neurobio 11994; 42: 1-32
   Google Scholar
• Kallioinen MJ, Heikkinen ER, Nystrom S. Histopathological and immunoh istochem ical changes in neurosurgical ly resected epilep-tic foci. Acta Neurochir (Wien) 1987; 89: 122-129
   Google Scholar
• Brigande JV, Wieraszko A, Albert MD, Balkema GW, Seyfried TN. Biochemical correlates of epilepsy in the El mouse: Analysis of glial fibrillary acidic protein and gangliosides. J Neurochem 1992; 58: 752–760
   PubMed Web of Science ®Google Scholar
• Dalby NO, Rondouin G, Lerner-Natoli M. Increase in GAP-43 and GFAP immunoreactivity in the rat hippocampus subsequent to perforant path kindling. ] Neurosci Res 1995; 41: 613–619
   PubMed Web of Science ®Google Scholar
• Karle J, Mikkelsen JD, Nielsen M. Increased neuropeptide Y (NPY) im mu noreactivity following antisense knock-down of GABAA receptor y2 subunit in rat hippocampus. Soc Neurosci Abstr 1996; 327: 5
   Google Scholar
• Mikkelsen JD, Karle J, Madsen TM. Intrahippocampal infusion of antisense oligodeoxynucleotideto the GABAA receptor y2 subunit enhances neuropeptide Y (NPY) gene expression. Brain Res Bull in press
   Google Scholar
• Johansen FF, O'hare MMT. Loss of somata! neuropeptide Y immunoreactivity in the rat hippocampus following transient cerebral ischemia. J Neurosurg Anesthesiol 1989; 1: 339–345
   PubMedGoogle Scholar
• Vezzani A, Sperk G, Colmers WF. Neuropeptide Y: Emerging evidence for a functional role in seizure modulation. Trends Neurosci 1999; 22: 25–30
   PubMed Web of Science ®Google Scholar
• Sperk G, Marksteined, Gruber B, Bellmann R, Mahata M, Ortler M. Functional changes in neuropeptide Y- and somatostatin-contain-ing neurons induced by limbic seizures in the rat. Neuroscience 1992; 50: 831–846
   PubMed Web of Science ®Google Scholar
• Baraban SC, Hollopeter G, Erickson JC, Schwartzkroin PA, Palmiter RD. Knockout mice reveal a critical anti-epileptic role for neuropeptide Y. J Neurosci 1997; 17: 8927–8936
   PubMedGoogle Scholar
• Woldbye DPD, Larsen PJ, Mikkelsen JD, Klemp K, Madsen TM, Bolwig TG. Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors. Nature Med 1997; 3: 761–764
   PubMed Web of Science ®Google Scholar